Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma
Journal of Surgical Oncology, 04/24/2012
Murakami Y et al. – Long–term results of adjuvant gemcitabine plus S–1 chemotherapy suggest this regimen may be safe and promising as treatment for this patient population.Methods
- Seventy patients who underwent surgical resection of pancreatic carcinoma were enrolled prospectively into this study.
- All patients received adjuvant chemotherapy with 10 cycles of gemcitabine plus S–1 every 2 weeks.
- Each cycle consisted of intravenous gemcitabine 700 mg/m2 on day 1 and oral S–1 50 mg/m2 for seven consecutive days, followed by a 1–week pause of chemotherapy.
- Long–term survival results of adjuvant gemcitabine plus S–1 chemotherapy were analyzed for this cohort.
- Median follow–up time was 51.2 months. Sixty percent of patients had node–positive disease and 79% of patients underwent R0 resection.
- Fifty–six patients (80%) completed adjuvant chemotherapy.
- Median overall and disease–free survival times were 35.4 and 23.8 months, respectively.
- Actuarial overall and disease–free survival rates were 89% and 64% at 1 year, 64% and 50% at 2 years, and 33% and 33% at 5 years, respectively.
- Only negative lymph node metastasis (P=0.010) independently correlated with long–term survival by multivariate analysis.